← Back to Search

Olaparib for Ovarian Cancer

Phase 2
Waitlist Available
Led By Sarah Taylor, MD
Research Sponsored by Sarah E Taylor
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 42 months
Awards & highlights

Study Summary

This trial will test if delaying cancer treatment will result in a longer time until the next or different treatment is needed, and will also evaluate the impacts of delayed treatment on symptoms, physical function, quality of life, and finances.

Eligible Conditions
  • Ovarian Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 42 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 42 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to Next Therapy
Secondary outcome measures
Adverse Events Possibly, Probably or Definitely Related to Treatment
Assessment of Survivor Concerns (ASC) Worry Subscale and Impact of Event Scale (IES-R)
Modified Collection of Indirect and Non-medical Direct Costs (COIN)
+5 more

Side effects data

From 2023 Phase 3 trial • 154 Patients • NCT02184195
49%
Nausea
47%
Fatigue
38%
Diarrhoea
29%
Abdominal pain
29%
Anaemia
28%
Constipation
27%
Decreased appetite
27%
Back pain
26%
Vomiting
21%
Arthralgia
19%
Pyrexia
18%
Asthenia
13%
Rash
13%
Nasopharyngitis
11%
Alanine aminotransferase increased
11%
Dyspnoea
10%
Neuropathy peripheral
10%
Cough
10%
Abdominal pain upper
10%
Dyspepsia
10%
Anxiety
10%
Pruritus
9%
Hyperglycaemia
9%
Aspartate aminotransferase increased
9%
Dizziness
9%
Thrombocytopenia
9%
Oedema peripheral
9%
Pain in extremity
9%
Insomnia
9%
Stomatitis
9%
Dry mouth
9%
Headache
9%
Neutropenia
8%
Blood creatinine increased
8%
Weight decreased
7%
Dysgeusia
7%
Blood alkaline phosphatase increased
7%
Neutrophil count decreased
7%
Muscle spasms
7%
Influenza
7%
Influenza like illness
7%
Myalgia
7%
Peripheral sensory neuropathy
7%
Gamma-glutamyltransferase increased
6%
Hypertension
6%
Platelet count decreased
6%
Depression
6%
Lymphopenia
6%
Gastrooesophageal reflux disease
6%
Abdominal distension
5%
Musculoskeletal pain
3%
Flank pain
2%
Cholangitis
2%
Flatulence
2%
Paraesthesia
1%
General physical health deterioration
1%
Bladder papilloma
1%
Pneumonia pneumococcal
1%
Abdominal infection
1%
Bartholinitis
1%
Pneumonia
1%
Cerebrovascular accident
1%
Pneumothorax
1%
Gastric varices haemorrhage
1%
Large intestinal obstruction
1%
Cholecystitis
1%
Anastomotic haemorrhage
1%
Device occlusion
1%
Stent malfunction
1%
Bronchiolitis
1%
Empyema
1%
Syncope
1%
Incisional hernia
1%
Device dislocation
1%
Obstruction gastric
1%
Cardiac failure
1%
Vascular stenosis
1%
Pleural effusion
1%
Incarcerated inguinal hernia
1%
Urinary tract infection
1%
Hypothyroidism
1%
Transient ischaemic attack
1%
Infusion related reaction
1%
Duodenal perforation
1%
Melaena
1%
Bile duct obstruction
1%
Pancreatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Olaparib 300 mg Twice Daily (bd)
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: OlaparibExperimental Treatment1 Intervention
Olaparib dosed at 300mg orally twice daily, started when CA125 rises by two-fold of nadir value.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Olaparib
FDA approved

Find a Location

Who is running the clinical trial?

Sarah E TaylorLead Sponsor
American Society of Clinical OncologyOTHER
33 Previous Clinical Trials
147,550 Total Patients Enrolled
Sarah Taylor, MDPrincipal InvestigatorUniversity of Pittsburgh

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is Olaparib typically employed to help patients?

"Olaparib has been seen to provide relief from advance directives, as well as malignant neoplasms of the ovary, primary peritoneal cancer, and psychosomatic hallucinations."

Answered by AI

Has Olaparib been given the go-ahead by federal regulators?

"Olaparib has been assigned a rating of 2 on our safety scale due to the limited data regarding efficacy. However, there is some evidence demonstrating its safety profile from Phase 2 trials."

Answered by AI

How many participants are being treated in this trial?

"At this time, there is no recruitment for the clinical trial posted on June 29th 2020. However, if you are searching for other investigations related to ovarian cancer and Olaparib respectively, 914 studies and 188 trials are currently accepting participants."

Answered by AI

Is there an ongoing recruitment of participants for this investigation?

"According to the info available on clinicaltrials.gov, this trial is not recruiting at present. It was initially posted in June 2020 and modified lastly in August 2022; however, there are 1102 other trials that require participants right now."

Answered by AI

Is this particular clinical trial pioneering a new form of treatment?

"The initial research into olaparib began in 2005, with a trial funded by AstraZeneca involving 98 participants. This was followed shortly after by Phase 1 drug approval for the medication and today there are 188 active studies taking place across 59 different nations and 1468 cities globally."

Answered by AI

Has Olaparib been studied in other research scenarios?

"Presently, there are 188 research studies dedicated to Olaparib with 27 in the final phase of testing. Most experiments for Olaparib take place in Houston, Texas yet thousands more trial sites can be found throughout the country."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
Sarah E Taylor 2020. "Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04377087.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top